Helicid

Helicid is a pharmaceutical product that contains the proton‑pump inhibitor omeprazole as its sole active ingredient. It is marketed in the European Union and is supplied in oral dosage form, although the specific strength and tablet or capsule format are not disclosed in the available data. Helicid belongs to the class of acid‑related disorder treatments and works by reducing gastric acid secretion in the stomach.

Helicid, containing omeprazole, is indicated for several acid‑related gastrointestinal conditions that require reduction of gastric acidity.

- Gastroesophageal reflux disease (GERD) to relieve heartburn and regurgitation. - Erosive esophagitis to promote healing of inflamed esophageal tissue. - Peptic ulcer disease, including duodenal and gastric ulcers, to support ulcer resolution. - Part of combination therapy for Helicobacter pylori eradication. - Prevention of ulcer recurrence in patients at risk from non‑steroidal anti‑inflammatory drugs (NSAIDs).

The safety profile of Helicid reflects the typical adverse events reported for omeprazole, ranging from mild and transient to rare but serious reactions.

Common: - Headache. - Diarrhea or loose stools. - Nausea or abdominal discomfort. - Flatulence or bloating.

Serious: - Severe allergic reactions such as rash, itching, swelling, or difficulty breathing. - Low magnesium levels (hypomagnesemia) that may cause muscle cramps or irregular heartbeat. - Clostridioides difficile‑associated colitis presenting with persistent diarrhea.

Before starting Helicid, certain precautionary considerations should be reviewed to ensure safe and effective use.

- Assess renal or hepatic impairment, as dose adjustment may be required. - Use cautiously in patients with a history of osteoporosis or fractures, due to potential impact on calcium absorption. - Evaluate for possible vitamin B12 deficiency with long‑term therapy. - Consider the risk of rebound acid hypersecretion after abrupt discontinuation. - Review pregnancy and lactation status, as safety data are limited. - Monitor for signs of infection, especially gastrointestinal infections, during prolonged treatment.

Helicid can affect the pharmacokinetics of several other medicines; awareness of these interactions helps to avoid reduced efficacy or increased toxicity.

Avoid: - Antiretroviral agents such as atazanavir or nelfinavir, where reduced plasma concentrations have been reported. - Certain antifungal drugs like ketoconazole or itraconazole that require an acidic environment for absorption.

Use with caution: - Warfarin, because omeprazole may enhance anticoagulant effect and increase INR. - Clopidogrel, as omeprazole can inhibit its activation, potentially diminishing antiplatelet activity. - Digoxin, where omeprazole may increase serum levels and require monitoring.